MDxHealth is trading at $0.52, down 14.26% in pre-market after suspending its $110–115 million full-year 2026 revenue guidance. - Announced October 15, preliminary Q3 revenue was $22.7 million, unchanged from the prior-year quarter. - Management said unexpected sales-force turnover disrupted execution, leaving revenue short of expectations. - Full Q3 results are expected November 12; no pre-market volume information was provided.